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INTRODUCTION
Salivary gland tumors are relatively rare, 
comprising about 3 to 4% of all neck and face 
tumors. The malignant lymphoepithelial lesion 
(MLEL) is a variety of the planocellular type, in 
which intense lymphoid infiltration is found in 
its fibrous stroma. There is a 3:2 female to male 
incidence of MLEL, except among the Chinese, 
in which the tumor is more prevalent in males.1
The MLEL involves only salivary glands, 
generally the parotid gland; about 15% of cases 
occur in the submandibular gland.1 The pathoge-
nesis has been related to the Epstein-Barr virus 
(EBV), because of the detection of viral onco-
proteins in tumor cell cultures. After an infection, 
the virus may remain at a low level of activity 
for a prolonged period in the epithelial salivary 
ducts, and in a latent state in B2 lymphocytes.
The EBV has been correlated with 
several epithelial malignancies, especially undi-
fferentiated nasopharyngeal carcinomas (NPC). 
Recent studies have also suggested a strong 
association between EBV expression and the 
MLEL in salivary glands among the Taiwanese, 
South China Chinese, and Eskimos.3
Patients with the MLEL are apparently 
more prone to regional and distance metastases. 
The incidence of regional metastases among 
Eskimos is 30% to 50%; among Asians, the in-
cidence is 10%.1
CASE REPORT
A female white patient aged 75 years 
presented with a right submandibular node 
on October 2006. Ultrasound and fine-needle 
aspiration puncture were done; the latter was 
negative for neoplastic cells. The right salivary 
gland was partially removed on December 2006.
The patient was referred to an oncolo-
gy unit on January 2007, since histology of the 
surgical specimen diagnosed an undifferentiated 
submandibular gland lymphoepithelioma-like 
carcinoma. The local and regional examination 
revealed a surgical scar on the right subman-
dibular region; there were no palpable neck 
nodes, and examination of the mouth and naso-
fibroscopy were normal. A review of the slides 
confirmed the diagnosis. Immunohistochemistry 
also suggested a lymphoepithelial carcinoma 
(WHO) with positive cytokeratins 40, 48, 50 and 
50.6 kDa. Face and neck computed tomography 
did not reveal enlarged lymph nodes or lesions 
in the rhinopharynx.
The initial treatment consisted of alloy 
collimated electron radiotherapy on the right 
field over the entire operated area and the first 
drainage level. The initial dose was 5,000 cGy, 
12 MeV, 25 fractions (5 weekly fractions) follo-
wed by 1,000 cGy reinforcement in 5 fractions 
to reach 6,000 cGy; the radiotherapy period was 
23 February 2007 to 13 April 2007.
At present, the patient has no evidence 
of local or regional recurrences; the irradiated 
area is not fibrotic. Imaging demonstrates ab-
sence of the right submandibular gland (Fig. 1).
DISCUSSION
The nasopharynx, the salivary glan-
ds and the thymus derive from the primitive 
pharynx. Undifferentiated carcinomas in these 
sites are histologically identical.1 Thus, NPC are 
indiscernible.
It is important to differentiate the MLEL 
from NPC metastases to salivary glands. If the 
diagnosis is incorrect, the NPC will not receive 
the appropriate radiotherapy dose even if ad-
juvant therapy is done in salivary glands. Thus, 
to establish the diagnosis of the MLEL, careful 
nasofibroscopy of the upper respiratory tract and 
random biopsies of the nasopharynx should be 
carried out to discard metastatic disease.1
The MLEL tumors may be infiltrative 
with indistinct limits, partially circumscribed, 
or multinodular. Regional metastases first occur 
around the parotid gland, the superior region of 
the neck, the retroauricular lymph nodes; later, 
they involve supraclavicular and paratracheal 
lymph nodes.1 Computed tomography of the 
cranial base and nasopharynx should be carried 
out for the diagnosis, staging, and follow-up. 
Magnetic resonance imaging is better for evalu-
ating recurrences and soft tissue involvement.4
Because of the malignant behavior of 
the lymphoepithelioma and the high metastatic 
rate to neck lymph nodes during the initial stages 
(stages I and II), neck dissection is recommen-
ded.5 Some studies have showed that complete 
surgical excision with free margins is mandatory.
Tumor removal with wide margins, 
neck dissection, and postoperative combined 
radiotherapy and chemotherapy comprise the 
treatment of the MLEL in patients at advanced 
stages of the disease (stages III and IV). Removal 
of the tumor and neck dissection, followed by 
postoperative radiotherapy, comprise the treat-
ment for patients at initial stages of the disease 
(stages I and II). Salvage surgery and chemothe-
rapy are recommended for patients with local 
or regional recurrences. Thus, surgeons should 
assess the tumor stage and to seek evidence 
of neck disease when defining the treatment.5
COMMENTS
Because of the high recurrence rate 
and metastases of the MLEL, the ideal treatment 
should be aggressive; this includes extensive 
resection with tumor-free margins, dissection of 
neck lymph node metastases, and electron ra-
diotherapy or radiotherapy and adjuvant chemo-
therapy when distance metastases are present.
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Figure 1. Operated site with no local or regional recurrences.
